From Injection to Oral
Rybelsus - The First Oral GLP-1 Receptor Agonist
Talk up your brand.
Use this space to add more details about your site, a customer quote, or to talk about important news.
Do You Know?
Since 1923, Novo Nordisk’s core expertise lies in discovering and developing new protein- and peptide-based drug therapies.
Research into oral GLP-1 Receptor Agonist started as early as 2008.
Semaglutide has a molecular weight of 4.1 kDa, which is even larger than our body’s GLP-1 hormone at 3.3 kDa.
Patient’s Guide to Rybelsus
To ensure an optimal environment for the absorption of Semaglutide, Rybelsus is to be
Taken with an empty stomach
Taken with a glass of water (180ml)
Wait 30 minutes before consuming any food
Talk to our Representative
We
Vui lòng liên hệ với chúng tôi qua
